Skip to content
buyModerate cluster of 5

Thomas J. Schall bought $89k of IMRX

director at Immuneering Corp. 40,485 shares at an average of $2.21, traded Jun 17, 2025, filed Jun 18, 2025.

Conviction score
49
Value
$89k
40,485 shares
Holdings after
43,385
+1396% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Director
    +15
  • Trade size
    $89k at market
    +9
  • Relative to holdings
    Holdings up 1396%
    +10
  • Price context
    No price history yet
    0
  • Cluster
    5 insiders buying within 14 days
    +15
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Rows in this filing

Every transaction in Form 4 0001790340-25-000079, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jun 17, 2025POpen-market purchase
Class A Common Stock
+40,485$2.21$89k43,385Jun 18, 2025

Related signals

Other insiders at Immuneering Corp and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
47Moderate
IMRXbuy 5
Immuneering Corp
Thomas J. Schall
director
$35k
9,500 shares
+22%
36Weak
IMRXbuy 5
Immuneering Corp
Harold Eugene Brakewood
Chief Business Officer
$4,804
1,900 shares
+49%
36Weak
IMRXbuy 5
Immuneering Corp
Brett Matthew Hall
CHIEF SCIENTIFIC OFFICER
$35k
13,422 shares
+4%
44Moderate
IMRXbuy 5
Immuneering Corp
Peter Feinberg
director
$63k
25,000 shares
+22%
42Moderate
IMRXbuy 5
Immuneering Corp
Benjamin J. Zeskind
PRESIDENT AND CEO
$50k
21,000 shares
+1%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Thomas J. Schall bought $89k of IMRX | InsiderTell